Long
Q1 to Q2 2019 Epidiolex & Sativex
long entry from $100; PT1 $125 PT2 $143
Q1 2019 - FDA meeting outcome on Sativex;
Sativex (nabiximols) is an oromucosal spray of a formulated botanical extract of cannabis
that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio
Approved in >25 countries outside of the U.S. for the treatment of spasticity due to multiple sclerosis (MS); sold via marketing partners
• Three positive Phase 3 trials completed in Europe
U.S. development and commercialization plan
• Evaluating NDA path for MS spasticity
• Potential for multiple indications
• >10 additional placebo-controlled trials completed
• Significant U.S. life cycle management opportunities
Epidiolex
EMA decision Q1 2019
Phase 3 TSC data Q2 2019
Dravet 2 data presentation Q2 2019
Rett syndrome Phase 3 study start Q2 2019
TSC FDA sNDA submission Q4 2019
Sativex
FDA meeting outcome Q1 2019
Phase 3 MS study start 2H 2019
Cash at 30 September 2018
$354.9m
Net cash from October financing
$324.2m
Q ending 31 December 2018 operating expense guidance
$90m–$100m
Q1 2019 - FDA meeting outcome on Sativex;
Sativex (nabiximols) is an oromucosal spray of a formulated botanical extract of cannabis
that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio
Approved in >25 countries outside of the U.S. for the treatment of spasticity due to multiple sclerosis (MS); sold via marketing partners
• Three positive Phase 3 trials completed in Europe
U.S. development and commercialization plan
• Evaluating NDA path for MS spasticity
• Potential for multiple indications
• >10 additional placebo-controlled trials completed
• Significant U.S. life cycle management opportunities
Epidiolex
EMA decision Q1 2019
Phase 3 TSC data Q2 2019
Dravet 2 data presentation Q2 2019
Rett syndrome Phase 3 study start Q2 2019
TSC FDA sNDA submission Q4 2019
Sativex
FDA meeting outcome Q1 2019
Phase 3 MS study start 2H 2019
Cash at 30 September 2018
$354.9m
Net cash from October financing
$324.2m
Q ending 31 December 2018 operating expense guidance
$90m–$100m
Note
Let this winner run!Trade closed manually
Profits taken at 150. Watch on Q4 earnings. Epidiolex
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.